Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingNot Applicable A double-blind, randomized, placebo-controlled, multicenter phase III study of intravenous terlipressin in patients with hepatorenal syndrome type 1
100 Clinical Results associated with Curatis Pharma GmbH
0 Patents (Medical) associated with Curatis Pharma GmbH
100 Deals associated with Curatis Pharma GmbH
100 Translational Medicine associated with Curatis Pharma GmbH